Idarubicin: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Idarubicin. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Infection | 97% |
| Nausea & vomiting | 82% |
| Hair loss | 77% |
| Abdominal cramps/diarrhea | 73% |
| Hemorrhage | 65% |
| Mucositis | 55% |
| Dermatologic | 46% |
| Mental status | 41% |
| Pulmonary-clinical | 39% |
| Fever (not elsewhere classified) | 28% |
| Headache | 24% |
| Cardiac-clinical | 24% |
| Neurologic- peripheral nerves | 9% |
| Seizure | 5% |
| Pulmonary allergy | 4% |
| Cerebellar | 4% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Idarubicin Hydrochloride injection, USP in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
Source: FDA labeling via NIH DailyMed (set b9b337d5…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.